17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
Authors:
- Cristina BagaceanCBCristina Bagacean
- Adrian TempesculATAdrian Tempescul
- David TernantDTDavid Ternant
- Anne BanetABAnne Banet
- Nathalie Douet-GuilbertNDNathalie Douet-Guilbert
- Anne BordronABAnne Bordron
- Boutahar BendaoudBBBoutahar Bendaoud
- Hussam SaadHSHussam Saad
- Mihnea ZdrengheaMZMihnea Zdrenghea
- Christian BerthouCBChristian Berthou
- Gilles PaintaudGPGilles Paintaud
- Yves RenaudineauYRYves Renaudineau
Open Access
- 29 January 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 22
Abstract
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. However, some patients experience treatment resistance or rapid relapses, and in particular, those harboring a 17p/TP53 deletion (del(17p)). This resistance could be explained by a chemo-resistance, but it could also result from the direct impact of del(17p) on the pharmacokinetics of rituximab, which represents the aim of the present study. Accordingly, 44 CLL patients were included in the study, and among them 9 presented a del(17p). Next, a total of 233 rituximab sera were selected for a pharmacokinetic study and analyzed in a two-compartment model showing important differences when del(17p) CLL patients were compared with non-del(17p) patients treated with rituximab and chemotherapy: (1) clearance of rituximab was faster; (2) central volume of rituximab distribution V1 (peripheral blood) was reduced while peripheral volume V2 (lymphoid organs and tissues) was increased; and (3) the rate of rituximab elimination (Kout) was faster. In contrast, the group with a better prognosis harboring isolated del(13q) presented a slower rate of elimination (Kout). Pharmacokinetic parameters were independent from the other factors tested such as age, sex, chemotherapy regimen (fludarabine/cyclophosphamide versus bendamustine), IGHV mutational status, and FCGR3A 158VF status. In conclusion, this study provides an additional argument to consider that del(17p) is effective not only to control chemoresistance but also monoclonal antibody activity, based on higher rituximab turnover.Keywords
This publication has 22 references indexed in Scilit:
- Anti-CD20 Monoclonal Antibodies in Chronic Lymphocytic Leukemia: From Uncertainties to PromisesImmunotherapy, 2016
- Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustionEuropean Journal of Haematology, 2015
- Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximabExperimental Hematology, 2014
- Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cellsAmerican Journal of Hematology, 2014
- Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapyAnnals of Hematology, 2011
- TP53 Mutation and Survival in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2010
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patientsBritish Journal of Haematology, 2008
- Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997Journal of Clinical Oncology, 2007
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002